Lead Product(s) : Guadecitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Neither study met the primary endpoint of statistically significant (p <0.05) improvement in overall survival (OS) compared with the control arm of physicians’ choice of alternative therapy.
Brand Name : SGI-110
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2020
Lead Product(s) : Guadecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?